| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.35 | 1e-14 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.27 | 0.0002 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.53 | 0.0009 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.002 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.09 | 0.004 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.47 | 0.005 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.005 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.13 | 0.005 |